Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma

The Oncotype DX 21-gene test can be used to predict chemotherapy efficacy in patients with estrogen receptor (ER)-positive and HER2-negative breast cancer; however, the data on the 21-gene recurrence score (RS) for mucinous breast carcinoma (MBC) are limited. The present study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Wang, Yun, Li, Taolang, Lv, Junyuan, Feng, Guoli, Tan, Na, Wang, Jinjing, Cheng, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442227/
https://www.ncbi.nlm.nih.gov/pubmed/34589150
http://dx.doi.org/10.3892/ol.2021.13032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442227/
https://www.ncbi.nlm.nih.gov/pubmed/34589150
http://dx.doi.org/10.3892/ol.2021.13032

Ejemplares similares